Multivariate models using NULISAseq and plasma p-tau217 for staging Alzheimer's disease.

ABSTRACT:

Introduction

Plasma phospho-tau217 (p-tau217) has been shown to demonstrate equal performance to cerebrospinal fluid (CSF) to predict amyloid beta (Aβ) positivity. Although such high-performing plasma tests provide confirmatory information on Aβ status, further information is desperately needed to discern optimal blood-based biomarkers (BBMs) across the Alzheimer's disease (AD) stage.

Methods

From the Australian Imaging, Biomarkers and Lifestyle study, 387 participants underwent [¹⁸F]NAV4694 (Aβ) and [¹⁸F]MK-6240 (tau) PET scans, a blood test to measure for p-tau217 (ALZpath and Lumipulse), and the Alamar Biosciences NULISASeq platform (120 central nervous system [CNS] and 250 inflammatory proteins). Individual p-tau217 assays were compared with selecte

SUBMITTER: Doecke JD 

PROVIDER: S-EPMC12550516 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature